Cibc World Markets Corp Buys New Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Cibc World Markets Corp purchased a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) in the fourth ...
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...
Hosted on MSN20d
Hutchmed concludes enrolment in Phase II trial of fanregratinib for IHCC
individuals with fibroblast growth factor receptor 2 (FGFR2) fusion/rearrangement. The single-arm, open-label registration study aims to assess the therapy’s safety, pharmacokinetics ...
Bank of New York Mellon Corp Purchases 50,190 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Bank of New York Mellon Corp raised its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 18.0% in the fourth quarter, according to the company in its most recent ...
pharmaphorum7d
Eisai files biliary tract cancer drug tasurgratinib in Japan
Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion ...
The Scientist1y
Epigenetic Changes Drive Cancer
One finding in particular caught Ding’s attention. Hypomethylation on fibroblast growth factor receptor 2 (FGFR2), a receptor tyrosine kinase (RTK) oncogene, increased transcript and protein abundance ...
Nasdaq22d
HUTCHMED Completes Enrollment in Phase II Trial of Fanregratinib for Intrahepatic Cholangiocarcinoma Patients with FGFR2 Fusion/Rearrangement
FGFR2 fusion occurs in 10-15% of IHCC patients ... (“IHCC”) patients with fibroblast growth factor receptor (“FGFR”)2 fusion/rearrangement. The study is a single-arm, multi-center, open ...